For other 5-HT 4 agonists, including clebopride, cinitapride and mosapride, there is relatively weak evidence to support efficacy [73], and cisapride, which appeared to be effective at relieving symptoms, was withdrawn from the market in 2000 due to concerns about cardiovascular safety [73]
This isn't withdrawal in the addiction senseit's simply your underlying medical condition reasserting itself
There is a lot going on physiologically that is out of ones control
Side effects: Mostly gastrointestinal and broadly consistent with incretin-based therapies: Nausea Diarrhoea Constipation Vomiting Discontinuation due to adverse events: 4 mg: 4.1% 9 mg: 6.9% 12 mg: 11.3% Placebo: 4.9% Some participants also experienced dysesthesia (abnormal skin sensations), though rates were lower than seen in earlier studies
Appeal denials : If your first authorization is denied, appeal
Your doctor's office will typically submit a request to Blue Cross Blue Shield, providing medical records and justification for the medication